secwatch / observer

8-K filed May 19, 2025 23:59 UTC ticker PTIX CIK 0001022899

m_and_a confidence high sentiment neutral materiality 0.90

Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors

Protagenic Therapeutics, Inc.new

Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025
Issued 117,690 common shares, 5,705 Series C Preferred, 950,000 Series C-1 Preferred, and 20,000 Series D Preferred to Phytanix stockholders
Appointed Barrett Evans as President and CEO, Colin Stott as COO and director, and Jennifer Chao as director; Andrew Slee promoted to Chief Development Officer
Resignations of directors Khalil Barrage, Tim Wright, and Robert Stein effective immediately before closing
Filed certificates of designation for Series C and C-1 Non-Voting Convertible Preferred Stock on May 15, 2025

item 1.01item 5.03item 2.01item 3.02item 3.03item 5.02item 7.01item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Khalil Barrage

Director

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025

Appointed

Colin Stott

Chief Operating Officer

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

Colin Stott as Chief Operating Officer and as a director of the Company

Appointed

Colin Stott

Director

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

Colin Stott as Chief Operating Officer and as a director of the Company

Appointed

Jennifer Chao

Director

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

Jennifer Chao as a director of the Company

Appointed

Barrett Evans

President and Chief Executive Officer

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company

Appointed

Barrett Evans

Director

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company

Departed

Robert Stein

Director

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025

Departed

Tim Wright

Director

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025

Role change

Andrew Slee

Chief Development Officer

PTIX · Protagenic Therapeutics, Inc.new

Effective: 2025-05-15
Filed: May 19, 2025 23:59 UTC

promoted Andrew Slee from his prior role of Chief Operating Officer to the Company’s Chief Development Officer, effective immediately upon the Closing on May 15, 2025

Source: SEC EDGAR

accession 0001641172-25-011387

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.